California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
 & Lead Plaintiff Deadline - January 5, 2017 - EconoTimes)
NEW YORK, Dec. 29, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Teva between February 10, 2015 and November 3, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Teva for alleged price manipulation; (3) as a result, Teva lacked effective internal controls; and (4) consequently, Teva’s public statements were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/teva or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Teva, you have until January 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
